文献速递头颈部肿瘤放疗

鼻咽癌淋巴结临床靶区个体化风险适配颅侧边界:挑战通用颅底规则

Individualized risk-adapted cranial border for nodal clinical target volume in nasopharyngeal carcinoma: challenging the universal skull base rule.
PubMed 文献 · Radiother Oncol · 2026-04-13

该回顾性研究纳入2014至2018年接受根治性IMRT的非转移性鼻咽癌患者627例,采用个体化CTVn勾画策略:颅侧边界主要设于寰椎横突下缘(C1),仅在IIb区淋巴结超过C1标志时选择性覆盖颅底。中位随访73个月,5年区域控制率达97.2%,仅1例在C1边界与颅底之间区域复发,且为GTVn原位失败。剂量学分析证实选择性策略显著保护腮腺。

要点

  • 个体化CTVn策略仅12.8%患者需颅底覆盖,87.2%可安全采用C1边界。
  • 中位随访73个月,5年区域控制率97.2%,C1-颅底间仅1例原位复发。
  • 选择性颅底覆盖显著保护腮腺,治疗比优于通用颅底覆盖指南推荐。

核心结论

  • 个体化风险适配CTVn勾画策略安全有效,在获得优异区域控制的同时显著减少放射暴露,治疗比优于现行指南推荐的通用颅底覆盖。

研究设计与样本

  • 回顾性研究,纳入2014至2018年在本机构接受根治性IMRT的非转移性鼻咽癌患者627例。

主要发现

  • 仅80例(12.8%)因淋巴结超过C1需颅底覆盖(A组),547例(87.2%)采用C1边界成功治疗(B组)。
  • 中位随访73个月,5年区域控制率达97.2%。
  • C1边界与颅底之间区域仅1例复发,为A组GTVn原位失败。
  • 剂量学分析证实选择性策略显著保护腮腺。

关键数值与推荐

  • CTVn颅侧边界主要设于寰椎横突下缘(C1),并在受累淋巴结上方至少外扩1 cm。
  • 仅当IIb区淋巴结超过C1标志时选择性覆盖颅底。

临床怎么用

  • 对非转移性鼻咽癌根治性IMRT,可依据IIb区淋巴结是否超过C1标志个体化决定颅底覆盖,避免通用颅底照射。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current international guidelines mandate routine skull base coverage for the nodal clinical target volume (CTVn) in nasopharyngeal carcinoma (NPC), however, this universal approach may lead to unnecessary radiation exposure. This study aimed to validate the feasibility of our optimized CTVn delineation strategy that challenges this conventional paradigm. METHODS: This retrospective study included non-metastatic NPC patients who received radical IMRT at our institution between 2014 and 2018. We employed an individualized CTVn delineation strategy: the cranial border was primarily set at the caudal edge of the lateral process of atlas (C1), with a minimal 1-cm margin above involved nodes. Skull base coverage was selectively applied only when level IIb nodes extended above the C1 landmark. RESULTS: A total of 627 patients were included. Applying this risk-adapted strategy, only 80 patients (12.8%) required skull base coverage due to nodal extension beyond C1 (Group A), while the majority (547 patients, 87.2%) were successfully treated with the C1-based border (Group B). With a median follow-up of 73 months, the 5-year regional control reached 97.2%. Notably, only one recurrence occurred in the region between the C1 border and skull base, which was an in-situ GTVn failure in Group A. Dosimetric analysis confirmed significant parotid gland sparing with this selective approach. CONCLUSION: Our optimized CTVn delineation strategy demonstrates both safe and effective, achieving excellent regional control while substantially reducing radiation exposure. This risk-adapted approach provides a superior therapeutic ratio compared to the universal skull base coverage recommended by current guidelines, offering a practical alternative for precision radiotherapy in NPC.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yan Z, Chen J, Zhu J, et al. Individualized risk-adapted cranial border for nodal clinical target volume in nasopharyngeal carcinoma: challenging the universal skull base rule. Radiother Oncol. 2026. PMID: 41980669. doi:10.1016/j.radonc.2026.111534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。